Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Leerink’s Jason Gerberry: deal is strategically important as it boosts rare disease drugs to about 65% of combined portfolio, cementing rare-disease leadership.
Leerink’s Michael Schmidt: Shire discontinued Baxalta’s BAX-335 hemophilia B gene therapy post-acquisition, raising questions about pipeline value embedded in…
Shire shares fell 9% on announcement. Wall Street questioned whether Shire paid too much given fierce hemophilia competition from Biogen, Roche, and BioMarin.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Shire acquired Baxalta for $32B for rare disease and hematology.
500 US cases/yr · $8.5B Global Immunoglobulin Market (2016)
Primary immunodeficiency diseases are >400 genetic disorders affecting the immune system. Baxalta was a leading IG manufacturer with GAMMAGARD and HyQvia.
Baxalta held top-3 position in global IG alongside CSL Behring and Grifols. IG supply was chronically constrained by plasma collection capacity.
400 US cases/yr · $11.0B Global Hemophilia Market (2016) · ~60% Hemophilia A Share of Total
~80%
Shire+Baxalta was acquired by Takeda in 2019 for $62B. The hemophilia franchise faced growing competition from Roche's Hemlibra (emicizumab) starting in 2018.
Shire and Baxalta announce agreed merger terms after six months of pursuit. Shire had initially approached Baxalta in August 2015 with an unsolicited bid that was rejected.
US antitrust review clears under Hart-Scott-Rodino Act. No divestitures required, reflecting limited product overlap between Shire's and Baxalta's rare disease portfolios.
Baxalta stockholders vote to adopt the merger agreement at a special meeting, clearing the final shareholder approval hurdle for the rare disease combination.
Shire completes $32B acquisition of Baxalta ($18 cash + 0.1482 Shire ADS per share), creating the global leader in rare diseases with ~$15B in combined revenue.
Shire reports 2017 revenue of $15.2B with $7B from legacy Baxalta products. Rare Disease Division accounts for ~$11B (72% of total). $500M synergy target on track.
Takeda completes $62B acquisition of Shire, absorbing the combined Shire-Baxalta rare disease franchise. The Baxalta hemophilia and immunology assets become part of Takeda's portfolio.
Shire-Baxalta created a rare disease leader but existed only ~2.5 years before Takeda's $62B takeout. Strategic thesis validated by the premium Takeda paid, but debt load made Shire a target.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Shire plc / Baxalta Inc. (this deal) | 2016 | $32.0B | 77 |
| Shire plc / Dyax Corp. | 2016 | $5.9B | 89 |
| Shire plc / New River Pharmaceuticals Inc. | 2007 | $2.6B | 88 |
| Shire plc / Jerini AG | 2008 | $521M | 85 |
| Shire plc / NPS Pharmaceuticals | 2015 | $5.2B | 78 |
| Shire plc / ViroPharma Incorporated | 2013 | $4.2B | 58 |
| Shire plc / Movetis NV | 2010 | $565M | 37 |
← Browse all deals · How we score deals
More: 2016 deals · Shire plc deals · Hematology deals